Thomas Hallam - Net Worth and Insider Trading
Thomas Hallam Net Worth
The estimated net worth of Thomas Hallam is at least $361 dollars as of 2024-06-20. Thomas Hallam is the CEO of Palisade Bio Inc and owns about 77 shares of Palisade Bio Inc (PALI) stock worth over $361. Details can be seen in Thomas Hallam's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Thomas Hallam has not made any transactions after 2022-08-16 and currently still holds the listed stock(s).
Transaction Summary of Thomas Hallam
Thomas Hallam Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Thomas Hallam owns 1 companies in total, including Palisade Bio Inc (PALI) .
Click here to see the complete history of Thomas Hallam’s form 4 insider trades.
Insider Ownership Summary of Thomas Hallam
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
PALI | Palisade Bio Inc | 2022-08-16 | director & Chief Executive Officer |
Thomas Hallam Latest Holdings Summary
Thomas Hallam currently owns a total of 1 stock. Thomas Hallam owns 77 shares of Palisade Bio Inc (PALI) as of August 16, 2022, with a value of $361.
Latest Holdings of Thomas Hallam
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
PALI | Palisade Bio Inc | 2022-08-16 | 77 | 4.69 | 361 |
Holding Weightings of Thomas Hallam
Thomas Hallam Form 4 Trading Tracker
According to the SEC Form 4 filings, Thomas Hallam has made a total of 3 transactions in Palisade Bio Inc (PALI) over the past 5 years, including 3 buys and 0 sells. The most-recent trade in Palisade Bio Inc is the acquisition of 53 shares on August 16, 2022, which cost Thomas Hallam around $10,000.
Insider Trading History of Thomas Hallam
- 1
Thomas Hallam Trading Performance
GuruFocus tracks the stock performance after each of Thomas Hallam's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Thomas Hallam is -53.86%. GuruFocus also compares Thomas Hallam's trading performance to market benchmark return within the same time period. The performance of stocks bought by Thomas Hallam within 3 months outperforms 0 times out of 3 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Thomas Hallam's insider trading performs compared to the benchmark.
Performance of Thomas Hallam
Thomas Hallam Ownership Network
Ownership Network List of Thomas Hallam
Ownership Network Relation of Thomas Hallam
Thomas Hallam Owned Company Details
What does Palisade Bio Inc do?
Who are the key executives at Palisade Bio Inc?
Thomas Hallam is the director & Chief Executive Officer of Palisade Bio Inc. Other key executives at Palisade Bio Inc include Chief Financial Officer John David Finley , Chief Medical Officer Mitchell Lawrence Jones , and Chief Operating Officer Robert Curtis Mcrae .
Palisade Bio Inc (PALI) Insider Trades Summary
Over the past 18 months, Thomas Hallam made no insider transaction in Palisade Bio Inc (PALI). Other recent insider transactions involving Palisade Bio Inc (PALI) include a net purchase of 51,000 shares made by John David Finley , a net purchase of 31,000 shares made by Donald Allen Williams , and a net sale of 300 shares made by Robert J. Trenschel .
In summary, during the past 3 months, insiders sold 0 shares of Palisade Bio Inc (PALI) in total and bought 2,000 shares, with a net purchase of 2,000 shares. During the past 18 months, 20 shares of Palisade Bio Inc (PALI) were sold and 7,333 shares were bought by its insiders, resulting in a net purchase of 7,313 shares.
Palisade Bio Inc (PALI)'s detailed insider trading history can be found in Insider Trading Tracker table.
Palisade Bio Inc Insider Transactions
Thomas Hallam Mailing Address
Above is the net worth, insider trading, and ownership report for Thomas Hallam. You might contact Thomas Hallam via mailing address: C/o Seneca Biopharma, Inc., 20271 Goldenrod Lane, Germantown Md 20876.